Study of NXT007 for people with hemophilia A
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests a new medicine called NXT007 for people with moderate or severe hemophilia A. The goal is to see if it is safe, well-tolerated, and can help prevent or reduce bleeding episodes, possibly reducing the need for standard treatments. You may be able to join if you have hemophilia A with or without inhibitors and meet other health requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with moderate or severe hemophilia A, with or without inhibitors (antibodies that make factor replacement less effective).
- If you have inhibitors, you must be using or willing to switch to a specific bypassing agent to manage bleeding episodes.
- You have not had gene therapy and are not planning to have it during the study.
- You have adequate blood, liver, and kidney function (determined by blood tests).
- You do not have other bleeding disorders or a history of blood clots, certain heart conditions, or high risk for a condition called TMA.
- You are willing to follow the study schedule and procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called NXT007 for people with hemophilia A. It compares NXT007 to standard factor VIII treatment to see if it works better at preventing bleeding episodes.
This trial tests if a new medicine, NXT007, is better than emicizumab at preventing bleeding episodes in people with hemophilia A. It may be an option for those with or without inhibitors who are willing to switch to a preventive treatment.
This study tests a new preventive treatment (NXT007) to help stop bleeding episodes in infants and children with hemophilia A. It aims to see if this treatment reduces the number of bleeds and improves quality of life.
This early-phase trial tests a new gene therapy called NGGT003 for men with severe hemophilia A. It aims to see if the treatment is safe and can help reduce bleeding episodes.
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
This trial tests a new gene therapy called SPK-8011QQ for adults with severe or moderately severe hemophilia A. The goal is to see if a single infusion can help your body produce its own factor VIII, reducing or stopping the need for regular factor VIII injections.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.